Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis.

Peng-Fei ZhangDan XieFeng WenQiu Li

Published in: Cancer medicine (2020)

Lenalidomide plus rituximab is not a cost-effective strategy compared with rituximab monotherapy for relapsed or refractory indolent lymphoma from a Chinese societal perspective.

Keyphrases

diffuse large b cell lymphoma
hodgkin lymphoma
multiple myeloma
chronic lymphocytic leukemia
stem cell transplantation
newly diagnosed
randomized controlled trial
acute lymphoblastic leukemia
combination therapy
low dose
open label